Journals | Policy | Permission

Journal of Clinical Medicine Research

Original Article

Volume 9, Number 10, October 2017, pages 838-843

Microalbuminuria: Correlation With Prevalence and Severity of Coronary Artery Disease in Non-Diabetics

Coronary artery disease (CAD) is a major cause of death and disability in both developed and developing countries. Advancing age, male sex, hypertension, diabetes mellitus, dyslipidemia and cigarette smoking are the independent risk factors for CAD [1], but they do not entirely explain the variation in cardiovascular disease incidence and mortality. Therefore, additional risk factors have been proposed to better identify patients potentially at risk for CAD, and urinary albumin is a promising candidate. Since the first description in 1974 [2], the presence of subclinical increases in urinary albumin excretion (UAE) has attracted attention, but much remains to be understood about the role of microalbuminuria (MAU) in non-diabetic individuals.

An increasing number of studies in different patient populations have reported that MAU is independently associated with cardiovascular morbidity and mortality in patients with diabetes [3], hypertension [4] and in the general population [5]. On the contrary, some other studies have also shown that this correlation is independent of renal function, hypertension, and diabetes [6, 7]. Data from several studies have demonstrated that MAU predicts development of ischemic cardiovascular events related to the development of atherosclerosis [8]. MAU is a common phenomenon in patients with cardiovascular disease worldwide. The term MAU is defined as urinary albumin levels of more than or equal to 30 - 300 mg/24 h in 24-h urine collection or albumin/creatinine ratio (ACR) of > 30 - 300 mg/g creatinine in random spot urine sample.

How MAU may be related to the development of atherosclerotic vascular disease is yet unclear. The currently accepted pathophysiological mechanism involves local injury to vascular smooth muscle cells and endothelium leading to cell proliferation and increase in vascular permeability [9, 10]. It is also reported that patients with MAU have a greater atherosclerosis burden in the form of multi-vessel CAD than in patients without it [11]. The association between albuminuria and cardiovascular events is well recognized [12], but few studies have addressed its correlation with the severity of CAD. This study was designed to investigate the relation between MAU, and the prevalence and severity of angiographically confirmed CAD in non-diabetic patients.

The present cross-sectional study was done among enrolled non-diabetic patients who were suspected for CAD and who underwent elective coronary angiography at NEIGRIHMS, Meghalaya, India, between January 2014 and August 2015. A total of 90 patients were enrolled during study period. Coronary angiography and assessment of MAU were done at the same time. Exclusion criteria were: diabetes, recent history of acute myocardial infarction or percutaneous transluminal coronary angioplasty, congestive heart failure, malignant diseases, presence of active infection, renal failure, serum creatinine level over 2 mg/dL or glomerular filtration rate (GFR) below 30 dL/min, using angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs). Initial evaluation of the patients by history and clinical examination were performed and recorded in the preformed data collection sheet. The data were collected on demographic and major cardiovascular risk factors including age, hypertension, diabetes mellitus, smoking and family history of CAD. Baseline laboratory investigations, e.g. complete blood count, chest roentgenogram, serum creatinine, serum electrolytes, fasting blood sugar, fasting lipid profile, electrocardiogram, and echocardiography, were done. Written consents were taken from all the patients. This study has been approved by institutional review committee and institute medical ethical committee.

We collected a morning random urine sample before coronary artery catheterization. Urinary albumin concentration was measured by turbidimetric immunological technique, using Beckman Coulter AU 2700 auto-analyzer. Urine ACR was calculated and reported as mg/g creatinine. Patients with albumin levels less than 30 mg/g of creatinine were defined as having normoalbuminuria, those with albumin levels 30 - 300 mg/g as having MAU.

The diagnostic procedure was performed by an experienced interventional cardiologist by using a Philips AlluraXper system via right femoral/right radial artery after performing local anesthesia with xylocaine. Interpretation of coronary angiogram was reviewed and angiographic severity of coronary artery disease was assessed by the number of vessels involved and SYNTAX score. The SYNTAX score is a tool to score complexity of CAD as follows: low (0 - 22), which is suitable for percutaneous coronary intervention (PCI), intermediate (23 - 32), which is suitable for either PCI or coronary artery bypass grafting (CABG), and high (≥ 33) where CABG is the preferred.

CAD was defined significant if there was ≥ 50% diameter stenosis in ≥ 1 major coronary artery.

Data were statistically described in terms of median and interquartile range (IQR) for quantitative, while categorical variables were expressed as number and percentages when appropriate. Comparison between the study groups was done using Mann-Whitney U-test for numerical, Chi-square and Fisher’s exact test for categorical data variables. Correlation between two numerical various variables was done using Pearson correlation coefficient (Spearman rho correlation coefficient equation for non-normal variables). P-values less than 0.05 were considered statistically significant. Statistical calculations were done using SPSS version 17.

The study included 90 non-diabetic patients with documented CAD by elective coronary angiography. The patients were classified into two groups based on the presence or absence of MAU: group I (MAU negative) consisted of patients with ACR level < 30 mg/g of creatinine (62 patients, 68.9%); group II (MAU positive) consisted of patients with ACR level 30 - 300 mg/g of creatinine (28 patients, 31.1%).

Demographic and clinical characteristics of all patients are shown in Table 1. Among patients with a positive MAU test, the median age was 54 years. There were no significant differences in the prevalence of hypertension, hypercholesterolemia, smoking and family history of CAD between the two groups.

Click to view

Table 1. Demographic and Clinical Characteristics of Patients

The distribution of CAD severity in the groups with and without MAU is presented in Table 2. The prevalence of double vessel CAD and triple vessel CAD was significantly higher in MAU positive group. Double vessel CAD was present in 24.1% of patients in group I, whereas it was present in 46.4% of patients in group II (P = 0.033). Of patients, 42.8% and 12.9% in group II and group I had triple vessel CAD respectively (P = 0.002).

Click to view

Table 2. Prevalence of Single Vessel, Double Vessel and Triple Vessel CAD

In group I, the correlation between MAU and severity of CAD was not statistically significant (r = - 0.035; P = 0.7850) (Table 3). On the other hand, presence of MAU exhibited a significant correlation with the severity of CAD (r = 0.094; P < 0.001) (Table 3).

Click to view

Table 3. Correlation Between Microalbuminuria and Number of Vessels Affected

The median ACR level in group I was 23 and in group II was 135.9 and this was statistically significant (P < 0.001). Also, there was significant difference in the median of ACR level among patients with single vessel disease (SVD), double vessel disease (DVD) and triple vessel disease (TVD) in group II (121 vs. 131 vs. 146, P < 0.001) (Table 4).

Click to view

Table 4. The Median ACR Level Among Patients With SVD, DVD and TVD in Group II

There was statistically significant difference between patients with and those without MAU regarding their SYNTAX scores. Patients with MAU had higher SYNTAX scores compared to those without MAU (28 ± 8 vs. 21 ± 6, P < 0.001), as shown in Table 5.

Click to view

Table 5. Median SYNTAX Score Between the Two Groups

In both groups, the severity of CAD by SYNTAX score was evaluated as low score ≤ 22 and intermediate or high score > 22. In group I, 45 patients (72.5%) had a low SYNTAX score ≤ 22 and 17 patients (27.4%) had an intermediate or high score > 22. In group II, six patients (21.4%) had a low SYNTAX score ≤ 22 and 22 patients (78.5%) had an intermediate or high score > 22 (Table 6).

Click to view

Table 6. Relation Between SYNTAX Score and ACR

Albumin excretion in the range of 30 - 300 mg/g of urinary creatinine is referred to as MAU. In the present study urinary ACR in spot urine sample was used to detect MAU, as it was shown to be equally sensitive and specific to 24-h urine collection method [13]. MAU is highly prevalent in several disease states. In this study, we found that the frequency of MAU was elevated in the study population (31.1%) which is significantly higher as compared to the general population which ranges from 5% to 7% in previous studies [14, 15]. Thus this study highlights that MAU is more frequent in non-diabetic patients with CAD than the general population and may be an important emerging risk marker for CAD. In the present study, there were no significant differences in the prevalence of hypertension, hypercholesterolemia, smoking and family history of CAD between the two groups. Differing from Gou et al [16], we did not find any relation between MAU with, hypercholesterolemia, cigarette smoking and hypertension. Although previous studies have reported the association between hypertension and MAU [17, 18], in the present investigation, we were not able to see a similar association. This diversity could be due to differences in sample size, race and geographic or nutritional factors.

The prevalence of double vessel CAD and triple vessel CAD was significantly higher in MAU positive group. The current study showed that patients with MAU have a greater atherosclerotic burden and a more severe CAD in the form of total number of vessels affected per patient than those without MAU. The results are in accordance with the previously reported findings [19-22]. In the present study, presence of MAU exhibited a significant correlation with the severity of CAD (r = 0.094; P < 0.001). Previous studies by Guo et al [16], Hoseini et al [21], and Al Saffar et al [22] also concluded that there was a positive correlation between severity of CAD and MAU in non-diabetic patients. The median ACR level in group I was 23 and in group II was 135.9 and this was statistically significant (P < 0.001). Hashim et al [20] in their study found a mean ACR of 131.8 ± 66.2 mg/g. In the present study, patients with MAU had higher SYNTAX scores compared to those without MAU (28 ± 8 vs. 21 ± 6, P < 0.001), showing that presence of MAU was associated with more complex CAD. This finding was in agreement with previous reports [19, 23]. The mechanism whereby MAU accelerates atherosclerosis is unclear. It is proposed that MAU indicates early and possibly reversible glomerular damage [4]. In non-diabetic persons with MAU, alterations in the extracellular matrix cause an increase in vascular permeability and this contributes to the development of endothelial dysfunction which promotes lipid influx into the vessel wall causing atherosclerotic changes [24]. It appears that aggressive treatment of MAU is beneficial in CAD patients. Several strategies are available to lower UAE. Widely known is the albuminuria-lowering effect of antihypertensive agents, which intervene with the renin angiotensin-aldosterone system. Ibsen et al [25] showed that a decrease in baseline albuminuria, which was more significant with losartan than with atenolol, results in significant reduction in cardiovascular events. Asselbergs et al [26] showed that the lowering of albuminuria with the ACEI fosinopril tended to be cardioprotective.

Gosling et al [27] and Haffner et al [28] considered MAU as an emerging cardiovascular risk factor in the non-diabetic patients. The present study agrees with these observations as it shows a significant MAU in non-diabetic CAD patients. This study has some limitations. First, it is a cross-sectional study, so a causal relationship cannot be established. Second, it is a single center study, with a small number of patients.

In our study, we found significantly high MAU levels in non-diabetic patients. The results of the present study indicate that non-diabetic patients with MAU have more extensive and complex angiographic CAD compared to those without MAU. Since the MAU is simple and relatively inexpensive investigation, early identification of MAU may influence the aggressiveness of management and ultimately the outcome of the disease.

1. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, Fortmann S, Sans S, Tolonen H, Evans A, et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet. 2000;355(9205):675-687.
   doi
2. Parving HH, Mogensen CE, Jensen HA, Evrin PE. Increased urinary albumin-excretion rate in benign essential hypertension. Lancet. 1974;1(7868):1190-1192.
   doi
3. Park HY, Schumock GT, Pickard AS, Akhras K. A structured review of the relationship between microalbuminuria and cardiovascular events in patients with diabetes mellitus and hypertension. Pharmacotherapy. 2003;23(12):1611-1616.
   doi pubmed
4. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens. 1998;16(9):1325-1333.
   doi pubmed
5. Romundstad S, Holmen J, Kvenild K, Hallan H, Ellekjaer H. Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trondelag Health Study (HUNT), Norway. Am J Kidney Dis. 2003;42(3):466-473.
   doi
6. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, Appleyard M, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation. 2004;110(1):32-35.
   doi pubmed
7. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106(14):1777-1782.
   doi pubmed
8. Pedrinelli R, Penno G, Dell'Omo G, Bandinelli S, Giorgi D, Di Bello V, Navalesi R, et al. Microalbuminuria and transcapillary albumin leakage in essential hypertension. Hypertension. 1999;34(3):491-495.
   doi pubmed
9. Taddei S, Virdis A, Mattei P, Ghiadoni L, Sudano I, Arrighi P, Salvetti A. Lack of correlation between microalbuminuria and endothelial function in essential hypertensive patients. J Hypertens. 1995;13(9):1003-1008.
   doi pubmed
10. Bakris GC, Randall O, Rahman M, et al. For the African American Study of Kidney Disease (AASK) Study Group. Association between cardiovascular risk factors and glomerular filtration rate at baseline in the AASK trial. J Am SocNephrol. 1998;9:139.
11. Hoseinii VN, Tazaki O. Relationship between Microalbuminuria and severity of coronary artey disease in non-diabetic patients. Iran Cardiovasc Res J. 2008;4:234-237.
12. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108(17):2154-2169.
    doi pubmed
13. Eknoyan G, Hostetter T, Bakris GL, Hebert L, Levey AS, Parving HH, Steffes MW, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis. 2003;42(4):617-622.
    doi
14. Atkins RC. The epidemiology of chronic kidney disease. Kidney Int Suppl. 2005;94:S14-18.
    doi pubmed
15. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, Van Gilst WH, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med. 2001;249(6):519-526.
    doi pubmed
16. Guo L, Cheng Y, Wang X, Pan Q, Li H, Zhang L, Wang Y. Association between microalbuminuria and cardiovascular disease in type 2 diabetes mellitus of the Beijing Han nationality. Acta Diabetol. 2012;49(Suppl 1):S65-71.
    doi pubmed
17. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as predictor of increased mortality in elderly people. BMJ. 1990;300(6720):297-300.
    doi pubmed
18. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet. 1988;2(8610):530-533.
    doi
19. Sukhija R, Aronow WS, Kakar P, Garza L, Sachdeva R, Sinha A, Mehta JL. Relation of microalbuminuria and coronary artery disease in patients with and without diabetes mellitus. Am J Cardiol. 2006;98(3):279-281.
    doi pubmed
20. Hashim R, Nisar S, urRehman K, et al. Microalbuminuria: association with ischemic heart disease in non-diabetics. J Ayub Med Coll Abbottabad. 2006;18(1):40-43.
    pubmed
21. Hoseini VN, Rasouli M. Microalbuminuria correlates with the prevalence and severity of coronary artery disease in non-diabetic patients. Cardiol J. 2009;16(2):142-145.
    pubmed
22. Al-Saffar HB, Nassir H, Mitchell A, Philipp S. Microalbuminuria in non-diabetic patients with unstable angina/non ST-segment elevation myocardial infarction. BMC Res Notes. 2015;8:371.
    doi pubmed
23. Lekatsas I, Kranidis A, Ioannidis G, Kalofoutis C, Tavernarakis A, Thalassinos N, Kalofoutis A, et al. Comparison of the extent and severity of coronary artery disease in patients with acute myocardial infarction with and without microalbuminuria. Am J Cardiol. 2004;94(3):334-337.
    doi pubmed
24. Schmitz A. Microalbuminuria, blood pressure, metabolic control, and renal involvement: longitudinal studies in white non-insulin-dependent diabetic patients. Am J Hypertens. 1997;10(9 Pt 2):189S-197S.
    doi
25. Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, et al. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens. 2004;22(9):1805-1811.
    doi pubmed
26. Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, de Zeeuw D, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110(18):2809-2816.
    doi pubmed
27. Gosling P. Microalbuminuria and cardiovascular risk: a word of caution. J Hum Hypertens. 1998;12(4):211-213.
    doi pubmed
28. Haffner SM, Stern MP, Gruber MK, Hazuda HP, Mitchell BD, Patterson JK. Microalbuminuria. Potential marker for increased cardiovascular risk factors in nondiabetic subjects? Arteriosclerosis. 1990;10(5):727-731.
    doi pubmed

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Journal of Clinical Medicine Research is published by Elmer Press Inc.